Abstract
A Randomized, Open-label, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Omalizumab in the Treatment of Persistent Moderate and Severe Allergic Asthma and Persistent Allergic Rhinitis in Pediatric Patients 6 to 17 years of age
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have